深耕生物医药材料细分赛道百瑞吉北交所成功过会丨A股融资快报

Core Viewpoint - Changzhou Baijie Bio-Medical Co., Ltd. (Baijie) successfully passed the listing committee's review meeting of the Beijing Stock Exchange on January 21, 2023, indicating a significant step towards its public offering [1]. Company Overview - Baijie, established in April 2008, is a high-tech enterprise primarily engaged in the research, production, and sales of biomedical materials [3]. - The company focuses on creating a leading research platform for bio-simulated tissue repair and regeneration materials through independent innovation [3]. Market Presence - As of June 30, 2025, Baijie's main products have been approved in approximately 2,100 hospitals in China, including around 600 top-tier hospitals [4]. - The company's products have also been successfully sold in developed countries such as the United States, Germany, the United Kingdom, France, and Australia, gaining international market recognition [4]. Financial Performance - Baijie's revenue has shown steady growth, with figures of 1.51 billion yuan in 2022, 1.98 billion yuan in 2023, 2.31 billion yuan in 2024, and 1.41 billion yuan in the first half of 2025 [5][6]. - Net profit figures for the same periods are 0.31 billion yuan, 0.50 billion yuan, 0.52 billion yuan, and 0.41 billion yuan, indicating a robust profitability and growth resilience [6]. Future Projections - For the full year of 2025, Baijie expects to achieve approximately 2.92 billion yuan in revenue and around 0.70 billion yuan in net profit, representing growth rates of 26.16% and 34.59% compared to 2024, respectively [8]. - The anticipated growth is attributed to increased downstream demand and improved surgical penetration rates of the company's anti-adhesion products [8]. Investment Plans - Baijie plans to raise 350 million yuan to expand its core product capacity and meet growing market demand, focusing on the construction of a biodegradable biomedical materials production base and R&D center [9]. - The project will involve the purchase of land and the construction of a facility in Changzhou, Jiangsu Province, covering an area of 10,200 m² with a total investment of 171.18 million yuan [9]. Competitive Advantage - Baijie possesses strong competitive advantages through its core independent R&D technologies, having obtained 19 domestic invention patents, 1 patent in Taiwan, and 32 PCT patents [10]. - The company has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, reflecting its innovation-driven development in the biomedical industry [10]. - With the accelerating global aging population and increasing healthcare demands, the regenerative medicine and biomaterials market presents significant growth opportunities for Baijie [10].